Special article

Challenges in Oral Lipid-lowering Therapy: Position Document of the Spanish Society of Cardiology

Manuel Anguita Sánchez, a Almudena Castro Conde, b Alberto Cordero Fort, c Xavier García-Moll Marimón, d Juan José Gómez Doblas, e José R. González-Juanatey, f,g Rosa María Lidón Corbi, g José Luis López-Sendón, b José Mostaza Prieto, h and Luis Rodríguez Padial i

a Servicio de Cardiología, Hospital Universitario Reina Sofía, Córdoba, Spain
b Servicio de Cardiología, Hospital Universitario La Paz, Madrid, Spain
c Servicio de Cardiología, Hospital Universitario de San Juan, San Juan de Alicante, Alicante, Spain
d Servicio de Cardiología, Hospital de la Santa Creu y Sant Pau, Barcelona, Spain
e Servicio de Cardiología, Hospital Universitario de Málaga, Málaga, Spain
f Servicio de Cardiología, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain
g Servicio de Cardiología, Hospital Universitario Vall d’Hebron, Barcelona, Spain
h Servicio de Cardiología, Hospital Carlos III, Madrid, Spain
i Servicio de Cardiología, Hospital Virgen de la Salud, Toledo, Spain

INTRODUCTION

Although safe, effective drugs are available for reducing circulating cholesterol concentrations, several epidemiologic studies have reported that most patients at high cardiovascular risk have low-density lipoprotein cholesterol (LDLc) values above the target levels recommended in clinical guidelines. 1 This is an important issue, considering that patients reaching the therapeutic target have a lower risk of cardiovascular complications and death. 2 There are several reasons for poor cholesterol control, such as poor treatment adherence among patients and treatment delays among physicians, but sometimes poor control is the result of ineffective lipid-lowering therapy.

Please visit http://dx.doi.org/10.1016/j.rec.2016.05.033 for further details.
In this regard, various patient subgroups may have difficulty reaching LDLc goals with the currently available drugs.3 These include the population of patients with familial hypercholesterolemia (FH), who generally show extraordinarily high LDLc concentrations that are difficult to reduce to recommended levels despite optimal lipid-lowering therapy,5,6 patients with partial or total statin intolerance, those unable to receive the recommended drugs,3 and numerous patients at very high cardiovascular risk who may require marked LDLc reductions that cannot be attained because of the considerable variability in the response to statins.7 Hence, it seems evident that new potent lipid-lowering agents are needed to replace statin therapy or be combined with these drugs.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein that regulates cholesterol metabolism by controlling degradation of low-density lipoprotein (LDL) receptors.8 After binding to an LDL particle, the LDL receptor internalizes into the cytoplasm with structures known as endosomes. The LDL-LDL receptor complex then dissociates: LDL is processed for degradation within the lysosomes, whereas the LDL receptors are recycled toward the cell surface where they bind to new LDL particles. This recycling process occurs approximately 150 times for each receptor. LDL receptors that are bound to a PCSK9 molecule cannot be recycled and are instead processed for lysosomal degradation together with LDL particles. Thus, PCSK9 inhibition reduces the number of receptors that will be degraded and increases their numbers on the cell surface, which lowers the plasma cholesterol concentration.

Two human monoclonal antibodies able to block PCSK9, alirocumab and evolocumab, are currently available in Spain. These agents, which are administered by subcutaneous injection every 2 or 4 weeks, are able to immediately (within hours) block the circulating PCSK9. Reductions in LDLc are perceptible at 48 hours after the start of treatment. Anti-PCSK9 antibodies reduce cholesterol concentrations in a dose-dependent manner, achieving decreases of up to 60% at a dose of 140 mg of evolocumab or 150 mg of alirocumab, administered every 2 weeks, with no significant adverse effects to date.9 In addition to reducing LDLc, both drugs can lower lipoprotein (a) levels by 20% to 30% and moderately lower triglyceride concentrations, with marginal elevations of high-density lipoprotein cholesterol levels. These reductions are cumulative to those obtained with statins or any other lipid-lowering drug.

Evolocumab and alirocumab have been approved by the Spanish Ministry of Health to be dispensed in the hospital setting for patients with the following indications, based on therapeutic positioning reports: patients with FH and LDLc plasma concentrations > 100 mg/dL despite the use of maximum statin doses, patients with established cardiovascular disease (ischemic heart disease, ischemic cerebrovascular disease, and peripheral arterial disease) and uncontrolled LDLc (> 100 mg/dL) with maximum tolerated statin doses, and any patients within these 2 groups who are intolerant to or have contraindications for statin use, and whose LDLc levels are > 100 mg/dL.

The Spanish Society of Cardiology has decided to establish a series of recommendations to position this therapeutic option, while being aware that clinical trials investigating the related morbidity and mortality are needed to provide a definitive basis for the indications. The complete document derived from this study is available on the Spanish Society of Cardiology website.10

The patient populations with priority to receive PCSK9 treatment and the LDLc concentrations above which PCSK9 would be indicated were established by consensus at participatory meetings. PCSK9 should probably only be used in patients who have already received optimal lipid-lowering therapy; that is, potent statins at the maximum tolerated doses with or without ezetimibe (if a patient exclusively treated with statins is far from achieving the therapeutic goals, anti-PCSK9 can be started if the attending physician considers that these goals will not be reached solely with the addition of ezetimibe).

PATIENTS IN SECONDARY PREVENTION

Patients with familial hypercholesterolemia and ischemic heart disease, showing low-density lipoprotein cholesterol > 70 mg/dL despite optimal lipid-lowering therapy

Familial hypertension (diagnosed clinically or genetically) is associated with a high risk of premature coronary disease and death.11 Patients with FH and cardiovascular disease have a very high risk of new complications.12 Although there are no data in this specific population, strict control of LDLc values to below 70 mg/dL improves prognosis following an acute coronary syndrome (ACS).12

Patients with recent ischemic heart disease (< 12 months) and low-density lipoprotein cholesterol > 100 mg/dL, despite optimal lipid-lowering therapy

This profile refers to patients diagnosed with ischemic heart disease during the previous year with persistent LDLc concentrations > 100 mg/dL despite optimal lipid-lowering therapy. This profile confers a particularly elevated risk because of the recent diagnosis of coronary disease, as the incidence of new events is higher in the first few months after diagnosis, especially in patients who have experienced an ACS.13 Within this group, patients at highest risk (ie, those with the most recent diagnosis and LDL values farthest from the therapeutic target) are considered to be those who will gain the greatest benefits.

Patients with stable ischemic heart disease and low-density lipoprotein cholesterol > 100 mg/dL despite optimal lipid-lowering therapy

Patients with stable coronary disease, including those with stable chronic angina and stabilized patients who have experienced a documented ACS (myocardial infarction with or without coronary revascularization therapy) more than 1 year previously, also have a high risk of new cardiovascular complications and death, although the risk is lower than that of patients with a recent ACS.14 Clinical practice guidelines on dyslipidemia and cardiovascular prevention consider this profile to confer very high cardiovascular risk.15 As in the previous profile, and although the risk of cardiovascular complications is not as high, initiation of anti-PCSK9 antibody treatment may also be indicated when LDLc values exceed 100 mg/dL.

Patients With a Recurrent Acute Coronary Syndrome and Those With Chronic Ischemic Heart Disease Who Experience an Acute Coronary Syndrome and Who Fail to Reach the LDLc Therapeutic Target of < 70 mg/dL Despite Optimal Lipid-lowering Therapy

Patients hospitalized for an ACS, defined as an ST-segment elevation acute myocardial infarction, a non-ST-segment elevation acute myocardial infarction, or unstable angina, do not have a benign long-term prognosis. Furthermore, if the ACS is recurrent, there is a greater risk of in-hospital and out-of-hospital
cardiovascular complications and death. In a retrospective study conducted in Spain and including 4345 patients who survived the hospital phase of an ACS, 21.5% had the combined event of cardiovascular death, acute myocardial infarction, or stroke over a 5-year follow-up. The risk was particularly high in the first year, when 34.8% of all events recorded during the entire observation period occurred. Clinical registries in large databases, which indicate the real-world situation, have cited 7-year mortality rates of 31% for men and 47% for women in the case of a first acute myocardial infarction, and 58% for men and 74% for women in recurrent acute myocardial infarction. These data demonstrate the high risk of recurrent disease and death in ACS patients and indicate the need to implement optimal cardiovascular protection measures, particularly in patients with more than 1 ACS episode and those with stable ischemic heart disease and an ACS episode. Therefore, the use of PCSK9 inhibitors is a priority in these patients if they do not achieve the LDLc therapeutic goal of <70 mg/dL despite maximum tolerated doses of oral lipid-lowering drugs.

Patients With Ischemic Heart Disease Who Have Not Reached the Therapeutic Target Because of Contraindications or Demonstrated Statin Intolerance

A subgroup of patients with ischemic heart disease do not achieve the therapeutic goal because of partial or complete statin intolerance. According to several studies, this group comprises approximately 15% of all patients with an indication for this treatment. In addition, it has been proven that discontinuation of statin therapy is associated with worsening of the cardiovascular prognosis in coronary patients. Therefore, in ischemic heart disease patients not reaching the LDLc therapeutic goal because of intolerance to high-dose statins and in those with contraindications for these drugs, the indication for PCSK9 inhibitors is probably justified to achieve the LDLc target value.

PATIENTS IN PRIMARY PREVENTION

Patients With Familial Hypercholesterolemia and No Cardiovascular Diseases Who Have Low-density Lipoprotein Cholesterol Values > 130 mg/dL Despite Optimal Lipid-lowering Therapy

As was mentioned above, FH is the most common hereditary condition associated with premature coronary disease. When FH remains untreated, the risk of experiencing a myocardial infarction before the age of 60 years is approximately 50% in men and 30% in women. Transmission of FH is by an autosomal-dominant inheritance mechanism with high penetrance that is expressed since birth. The condition is mainly produced by mutations in the LDL receptor gene and less commonly by apolipoprotein B and

---

**Figure.** Recommendations for PCSK9 inhibitor use in patients with high/very high cardiovascular risk (primary prevention) and patients with a clinical diagnosis of ischemic heart disease (secondary prevention). HeFH, heterozygous FH; HoFH, homozygous FH; LDL, low-density lipoprotein.
Patients without cardiovascular disease but at very high cardiovascular risk, with low-density lipoprotein cholesterol values > 130 mg/dL despite optimal lipid-lowering therapy

To be included in this profile, patients must meet the necessary criteria to be considered at high cardiovascular risk according to the European guidelines on dyslipidemia (type 2 or type 1 diabetes mellitus with target organ damage, estimated glomerular filtration rate < 60 ml/min/1.73 m², or a SCORE value > 10%). This profile probably also includes individuals with severe dyslipidemia other than FH, very high baseline cholesterol values, and a persistent LDLc concentration > 130 mg/dL despite optimal lipid-lowering therapy, such as individuals with familial combined hyperlipidemia or severe polygenic forms.

CONCLUSIONS

With the availability of new, highly effective lipid-lowering drugs such as PCSK9 inhibitors, the recommended LDLc target levels will be reached in a large number of patients (Figure). It is anticipated that the use of these agents will significantly decrease overall cardiovascular risk and mortality. Completion of ongoing clinical trials using several of these new monoclonal antibodies and investigation of morbidity and mortality will enable more accurate delineation of patient populations that will benefit from this therapy and will provide cost-effectiveness analyses.

Although the situations described in this document refer exclusively to atheromatous coronary heart disease, the same conclusions can be applied to other atherosclerosis-related conditions, such as peripheral arterial disease and cerebrovascular disease.

CONFLICTS OF INTEREST

M. Anguita Sánchez has received honoraria from Amgen for writing/revising manuscripts and for presentations. A. Cordero has received honoraria for consultancy work, expert testimony, and presentations from MSD, AstraZeneca, Menarini, Amgen, and Sanofi. J.M. Mostaza has received honoraria for consultancy work, talks, and educational presentations from Amgen and Sanofi. R.M. Lidón has received honoraria for consultancy work from AstraZeneca, and for expert testimony and presentations from Amgen and Ferrer. J.L. López-Sendón has received grants from Sanofi, Pfizer, Bayer, and GlaxoSmithKline, honoraria for participation in manuscript revisions from Pfizer, Bayer, and Merck, for writing/revising manuscripts from Aman, for consultancy work from Bayer, and for presentations from Menarini, Servier, Novartis, and Merck, and funding for travel expenses from Servier. X. García-Moll has received honoraria for presentations from Sanofi, Amen, and MSD, and funding for travel expenses from Sanofi. J.J. Gómez Doblas has received honoraria for presentations from Amen, Anh, MSD, Novartis, Astrazeneca, Ferrer, Servier, Bayer, and Menarini.

